InsideArbitrage Event Driven Monitor – June 10, 2025

Merger Arbitrage

1. ELEV: The acquisition of Elevation Oncology, Inc. (ELEV) by Concentra Biosciences, LLC, for a closing value of $21.32 million. Under the terms of the agreement, Concentra will acquire Elevation Oncology for $0.36 in cash per share of Elevation Oncology common stock, plus one non-tradeable contingent value right (CVR), which represents the right to receive all the net cash over $26.4 million post-closing, and 80% of any net proceeds received within five years of closing from the sale of EO-1022 that occurs within one year following closing. The cash consideration of $0.36 per share represents a 12.50% premium from the stock’s last close. (Press Release)
2. COOP: Mr. Cooper (COOP) announced that the waiting period under the HSR Act expired on June 4, 2025. The merger is expected to close in the fourth quarter of 2025.

You can check out new deals, all deal updates, and spreads on active deals in our Merger Arbitrage Tool for premium members here.

Only plus or premium subscribers can access this post. Subscribe today.